ResMed Inc. (RMD) Financial Statements

Executive TeamFinancials
SegmentsShareholders

ResMed financial statements at a glance

ResMed reported revenue of $5.65 billion for fiscal year 2026 (ended June 30, 2026), up 9.9% from fiscal year 2025. Net income was $1.52 billion, a net margin of 26.9%.

At the end of fiscal year 2026 it had total assets of $8.97 billion, total liabilities of $2.38 billion and shareholders' equity of $6.59 billion, with cash and short-term investments of $1.47 billion and total debt of $825.92 million.

Its operations brought in $1.81 billion of cash; capital spending was $177.17 million, leaving free cash flow of $1.63 billion.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended June 30, 2026.

RMD logo

ResMed Inc.

RMDUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
5.65B
Prev Year: 5.15B
YoY: +9.9%
Operating Revenue
5.65B
Prev Year: 5.15B
YoY: +9.9%
Other Non-operating Income (expense)
-9.15M
Prev Year: -5.26M
YoY: -74.2%
Special Income Charges
-21.75M
Prev Year: -2.03M
YoY: -970.7%
Restructuring and Mergers Acquisition
21.75M
Prev Year: 2.03M
YoY: +970.7%
Equity in Earnings of Affiliates
-8.06M
Prev Year: -6.66M
YoY: -21.1%
Depreciation Amortization Depletion
45.47M
Prev Year: 45.27M
YoY: +0.4%
Depreciation and amortization
45.47M
Prev Year: 45.27M
YoY: +0.4%
Amortization
45.47M
Prev Year: 45.27M
YoY: +0.4%
Amortization of Intangibles
45.47M
Prev Year: 45.27M
YoY: +0.4%
Cost of Revenue
2.20B
Prev Year: 2.09B
YoY: +5.3%
Gross Profit
3.45B
Prev Year: 3.05B
YoY: +13.0%
Operating Expense
1.54B
Prev Year: 1.37B
YoY: +12.8%
Selling General and Administrative
1.12B
Prev Year: 991.02M
YoY: +13.0%
Research and Development
378.29M
Prev Year: 331.28M
YoY: +14.2%
Operating Income
1.91B
Prev Year: 1.69B
YoY: +13.1%
Net Non Operating Interest Income Expense
49.91M
Prev Year: 4.11M
YoY: +1113.3%
Total Other Finance Cost
-49.91M
Prev Year: -4.11M
YoY: -1113.3%
Non-operating Interest Expense
-
Non-operating Interest Income
-
Pre-tax Income
1.92B
Prev Year: 1.68B
YoY: +14.4%
Provision for Income Taxes
396.12M
Prev Year: 276.84M
YoY: +43.1%
Net Income Common Stockholders
1.52B
Prev Year: 1.40B
YoY: +8.8%
Net Income
1.52B
Prev Year: 1.40B
YoY: +8.8%
Net Income Including Non-Controlling Interests
1.52B
Prev Year: 1.40B
YoY: +8.8%
Net Income from Continuing Operations
1.52B
Prev Year: 1.40B
YoY: +8.8%
Diluted NI Available to Com Stockholders
1.52B
Prev Year: 1.40B
YoY: +8.8%
Total Operating Income as Reported
1.89B
Prev Year: 1.69B
YoY: +11.9%
Total Expenses
3.74B
Prev Year: 3.46B
YoY: +8.3%
Basic EPS
-
Net Income from Continuing and Discontinued Operation
1.52B
Prev Year: 1.40B
YoY: +8.8%
Diluted EPS
-
Normalized Income
1.54B
Prev Year: 1.40B
YoY: +9.9%
Weighted Average Shares (basic)
-
Net Interest Income
49.91M
Prev Year: 4.11M
YoY: +1113.3%
Weighted Average Shares (diluted)
-
EBIT
1.91B
Prev Year: 1.69B
YoY: +13.1%
EBITDA
2.15B
Prev Year: 1.92B
YoY: +11.9%
Reconciled Cost of Revenue
2.00B
Prev Year: 1.90B
YoY: +5.4%
Reconciled Depreciation
244.15M
Prev Year: 235.81M
YoY: +3.5%
Net Income from Continuing Operation Net Minority Interest
1.52B
Prev Year: 1.40B
YoY: +8.8%
Interest Expense
-
Interest Income
-
Normalized EBITDA
2.17B
Prev Year: 1.93B
YoY: +12.9%
Tax Rate for Calcs
0.206
Prev Year: 0.165
YoY: +24.8%
Tax Effect of Unusual Items
-4.48M
Prev Year: -335.2K
YoY: -1236.5%
Total Unusual Items
-21.75M
Prev Year: -2.03M
YoY: -970.7%
Total Unusual Items Excluding Goodwill
-21.75M
Prev Year: -2.03M
YoY: -970.7%
Other Income Expense
-38.96M
Prev Year: -13.94M
YoY: -179.4%
Values in USD

ResMed key figures by fiscal year

FY2026FY2025FY2024FY2023FY2022
Revenue$5.7B$5.1B$4.7B$4.2B$3.6B
Gross profit$3.5B$3.1B$2.7B$2.4B$2.0B
Operating income$1.9B$1.7B$1.4B$1.2B$1.0B
Net income$1.5B$1.4B$1.0B$897.6M$779.4M
Diluted EPS––$6.92$6.09$5.30
Total assets$9.0B$8.2B$6.9B$6.8B$5.1B
Total liabilities$2.4B$2.2B$2.0B$2.6B$1.7B
Shareholders' equity$6.6B$6.0B$4.9B$4.1B$3.4B
Cash and short-term investments$1.5B$1.2B$238.4M$227.9M$273.7M
Total debt$825.9M$851.8M$873.9M$1.6B$917.6M
Operating cash flow$1.8B$1.8B$1.4B$693.3M$351.1M
Capital spending$177.2M$100.6M$114.9M$134.0M$156.0M
Free cash flow$1.6B$1.7B$1.3B$559.3M$195.1M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2015.

Questions and answers

What was ResMed's revenue in fiscal year 2026?

$5.65 billion, up 9.9% from $5.15 billion in fiscal year 2025.

How much profit does ResMed make?

ResMed reported net income of $1.52 billion for fiscal year 2026 (26.9% of revenue); operating income was $1.91 billion.

How much cash and debt does ResMed have?

At the end of fiscal year 2026: cash and short-term investments of $1.47 billion and total debt of $825.92 million.

What is ResMed's free cash flow?

$1.63 billion in fiscal year 2026 (operating cash flow of $1.81 billion minus capital spending of $177.17 million).

MoreResMed stock overviewResMed executive teamResMed shareholdersResMed revenue by segment
RelatedElectromedical and Electrotherapeutic Apparatus Manufacturing industryManufacturing sectorAlcon financialsPenumbra financialsCooper Companies financialsGlaukos financialsLantheus (LNTH)Axogen (AXGN)
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
© 2026 DataPorium. All rights reserved.|About & MethodologyPrivacy PolicyTerms of Use
LinkedInLinkedInXXYouTubeYouTube